Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023)
Cartesian Therapeutics (RNAC) reported Preferred Stock Liabilities of $296.9 million for Q4 2023, up 5837.02% quarter-over-quarter from $5.0 million in Q2 2016.
Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2015 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has 3 years of Preferred Stock Liabilities data on file, last reported at $296.9 million in Q4 2023.
- Preferred Stock Liabilities for Q4 2023 came in at $296.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $296.9 million (changed N/A YoY), and the FY2023 annual result was $296.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $296.9 million in Q4 2023 per RNAC's latest filing, from $5.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $296.9 million in Q4 2023 and troughed at $296.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 296.85 Mn |
| Jun 30, 2016 | 5.00 Mn |
| Dec 31, 2015 | 137.48 Mn |